tiprankstipranks
SVB Securities Remains a Buy on HilleVax, Inc (HLVX)
Blurbs

SVB Securities Remains a Buy on HilleVax, Inc (HLVX)

SVB Securities analyst David Risinger reiterated a Buy rating on HilleVax, Inc (HLVXResearch Report) on June 1 and set a price target of $30.00. The company’s shares closed yesterday at $18.76.

According to TipRanks, Risinger is a 4-star analyst with an average return of 6.7% and a 55.21% success rate. Risinger covers the Healthcare sector, focusing on stocks such as Johnson & Johnson, Eli Lilly & Co, and Halozyme.

The word on The Street in general, suggests a Strong Buy analyst consensus rating for HilleVax, Inc with a $29.00 average price target, representing a 54.58% upside. In a report released on May 29, Stifel Nicolaus also maintained a Buy rating on the stock with a $35.00 price target.

See today’s best-performing stocks on TipRanks >>

The company has a one-year high of $24.42 and a one-year low of $7.90. Currently, HilleVax, Inc has an average volume of 70.4K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

HilleVax Inc is a clinical-stage biopharmaceutical company. It is focused on developing and commercializing novel vaccines. The firm’s initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis (AGE) caused by norovirus infection.

Read More on HLVX:

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100
Bitcoin

Popular Articles